Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q4 2020 · 10-K
Revenue$7.15M$7.15M−56.5% vs Q4 2019 Net Income-$20.37M-$20.37MN/M vs Q4 2019 EPS Diluted-$0.60-$0.60N/M vs Q4 2019 Operating Incomederived-$15,646,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Operating Cash Flowderived-$13,512,000N/M Free Cash Flowderived-$13,748,000N/M Margins · derivedOperating margin-218.9%−158.5 pt vs Q4 2019
Net margin-284.9%−207.9 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 9, 2021 · 68 d after period end